Ataraxis AI, a frontier artificial intelligence (AI) research lab developing AI-powered tools for oncology, today announced Ataraxis™ Breast CTX, a new predictive capability within its Ataraxis Breast ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration CTx001 is an investigational AAV-based gene therapy designed to modulate ...

A Prescription Drug User Fee Act target date of May 31, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

AUSTIN, Texas — A local security company is taking a futuristic approach to public safety, teaming up with an Oregon-based robotics firm to patrol neighborhoods using artificial intelligence.

Contineum Therapeutics has pumped the brakes on two projects, freeing up resources to go full speed ahead in its pursuit of Bristol Myers Squibb in idiopathic pulmonary fibrosis (IPF). The San ...

Soon to be the official tool for managing Python installations on Windows, the new Python Installation Manager picks up where the ‘py’ launcher left off. Python is a first-class citizen on Microsoft ...

Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC). Perioperative nivolumab (NIVO) vs ...

(RTTNews) - Cingulate Inc.(CING), a biopharmaceutical company, Tuesday reported positive results from the Phase 3 pediatric study of its lead drug candidate CTx-1301 for the treatment of Attention ...

CTx-1301 is designed to deliver 3 separate releases of medication at different times and in different ratios. Topline data were announced from a phase 3 trial evaluating CTx-1301 for the treatment of ...

Cingulate Inc. completes FDA Pre-NDA meeting for ADHD drug CTx-1301 and secures $3 million grant for anxiety treatment CTx-2103. Cingulate Inc. announced the successful completion of a Pre-NDA meeting ...